Skip to content

Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion)

Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy: comparison of the evaluation system (PI-RADS category vs. PI-RADS + US evalutaion) - Detection of clinically significant prostate cancer with MRI-TRUS fusion image-guided biopsy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050631
Enrollment
80
Registered
2023-03-20
Start date
2023-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Suspected prostate cancer

Interventions

Ultrasound imaging (gray scale, Doppler, elastography)

Sponsors

Tokai University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Patients with PSA value and less than 20 ng/mL Patients who were suspected as having prostate significant cancer on MRI (with and larger than PI-RADS category 3) Patients who will be performed MRI-TRUS fusion image-guided biopsy and systematic biopsy with trans-perineal approach. Patients who agreed with the informed consent

Exclusion criteria

Exclusion criteria: Patients who disagreed with the informed consent Patients who are deemed inappropriate by the principal investigator or subinvestigator.

Design outcomes

Primary

MeasureTime frame
Significant cancer detection

Secondary

MeasureTime frame
1. Evaluation time of ultrasound 2. Revision rates of PI-RADS+US category from PI-RADS category 3. Difference of significant cancer detections between target and systematic biopsies 4. Safety (CTCAE v.5.0) during procedure and within 1 month after the procedure

Countries

Japan

Contacts

Public ContactSUNAO SHOJI

Tokai University Department of Urology

sunashoj@mail.goo.ne.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026